Brief: Iris Pharma Becomes A Subsidiary Of Abionyx Pharma

Abionyx Pharma SA

06/12/2021 06:59

Dec 6 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * TODAY ANNOUNCES FINAL COMPLETION OF A CONTRIBUTION IN KIND
TO
COMPANY OF 100% OF CAPITAL OF IRIS PHARMA HOLDING, WHO OWNS 100%
OF IRIS PHARMA
    * A POTENTIAL PORTFOLIO OF 3 NEW BIOLOGIC PRODUCT CANDIDATES
THAT
COULD ENTER INTO CLINICAL PHASE IN 14 POTENTIAL INDICATIONS IN
OPHTHALMOLOGY
    * IRIS PHARMA BECOMES A SUBSIDIARY OF ABIONYX PHARMA AND
REMAINS
INDEPENDENT IN ITS SERVICE ACTIVITIES FOR MAJOR PHARMACEUTICAL
AND BIOTECH COMPANIES IN OPHTHALMOLOGY SECTOR
    * COMPLETION OF CONTRIBUTION IN KIND FOLLOWS A SUCCESSFUL
CAPITAL
INCREASE IN CASH VIA A PRIVATE PLACEMENT FOR AN AMOUNT OF 4.2
MILLION EUROS AT A PRICE OF 3.60 EUROS PER SHARE
    * HE TRANSACTION WAS FULLY REMUNERATED BY ISSUANCE OF NEW
ABIONYX
PHARMA SHARES AT A PRICE SET AT 3.60 EUROS PER SHARE
    * NEW SHARES WILL BE ADMITTED TO TRADING ON EURONEXT PARIS
AS OF
DECEMBER 8, 2021
    * NEW SHARES WILL CARRY CURRENT DIVIDEND RIGHTS, WILL BE
ASSIMILATED TO OLD SHARES AND WILL ENJOY SAME RIGHTS

Source text for Eikon:  ID:nBw1fssh2a 
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))